» Articles » PMID: 37285096

Hepatectomy Before Primary Tumor Resection As Preferred Approach for Synchronous Liver Metastases from Rectal Cancer

Overview
Journal Ann Surg Oncol
Publisher Springer
Specialty Oncology
Date 2023 Jun 7
PMID 37285096
Authors
Affiliations
Soon will be listed here.
Abstract

Background: For patients with synchronous liver metastases (LM) from rectal cancer, a consensus on surgical sequencing is lacking. We compared outcomes between the reverse (hepatectomy first), classic (primary tumor resection first), and combined (simultaneous hepatectomy and primary tumor resection) approaches.

Methods: A prospectively maintained database was queried for patients with rectal cancer LM diagnosed before primary tumor resection who underwent hepatectomy for LM from January 2004 to April 2021. Clinicopathological factors and survival were compared between the three approaches.

Results: Among 274 patients, 141 (51%) underwent the reverse approach; 73 (27%), the classic approach; and 60 (22%), the combined approach. Higher carcinoembryonic antigen level at LM diagnosis and higher number of LM were associated with the reverse approach. Combined approach patients had smaller tumors and underwent less complex hepatectomies. More than eight cycles of pre-hepatectomy chemotherapy and maximum diameter of LM > 5 cm were independently associated with worse overall survival (OS) (p = 0.002 and 0.027, respectively). Although 35% of reverse-approach patients did not undergo primary tumor resection, OS did not differ between groups. Additionally, 82% of incomplete reverse-approach patients ultimately did not require diversion during follow-up. RAS/TP53 co-mutation was independently associated with lack of primary resection with the reverse approach (odds ratio: 0.16, 95% CI 0.038-0.64, p = 0.010).

Conclusions: The reverse approach results in survival similar to that of combined and classic approaches and may obviate primary rectal tumor resections and diversions. RAS/TP53 co-mutation is associated with a lower rate of completion of the reverse approach.

Citing Articles

Liver-first approach to the treatment of patients with synchronous colorectal liver metastases: a systematic review and meta-analysis.

Bulisani B, Leite M, Waisberg J Einstein (Sao Paulo). 2024; 22:eRW0596.

PMID: 39661858 PMC: 11634356. DOI: 10.31744/einstein_journal/2024RW0596.


CEA Rebound After Discontinuation of Pre-Hepatectomy Chemotherapy Predicts Worse Outcomes After Resection of Colorectal Cancer Liver Metastases.

Haddad A, Lendoire M, Uppal A, Maki H, Folkert I, Wang Y Ann Surg Oncol. 2024; 32(2):1021-1032.

PMID: 39516416 PMC: 11773633. DOI: 10.1245/s10434-024-16370-x.


Treatment Strategies' Impact on Progression-Free Survival According to RMST Function in Metastatic Colorectal Cancer Patients: A Retrospective Study from Romania.

Pirvu E, Severin E, Patru R, Nita I, Toma S, Croitoru B J Clin Med. 2024; 13(20).

PMID: 39458124 PMC: 11508923. DOI: 10.3390/jcm13206174.


The Top Ten Annals of Surgical Oncology Original Articles on Twitter/X: 2020-2023.

Jain A, Schultz K, Brainerd M, Murimwa G, Fleming A, Fackche N Ann Surg Oncol. 2024; 31(13):9100-9111.

PMID: 39138773 PMC: 11560640. DOI: 10.1245/s10434-024-15936-z.


Challenges and Opportunities for Precision Surgery for Colorectal Liver Metastases.

OConnell R, Hoti E Cancers (Basel). 2024; 16(13).

PMID: 39001441 PMC: 11240734. DOI: 10.3390/cancers16132379.


References
1.
Fleming C, Vendrely V, Rullier E, Denost Q . Organ preservation in rectal cancer: review of contemporary management. Br J Surg. 2022; 109(8):695-703. DOI: 10.1093/bjs/znac140. View

2.
Snyder R, Hao S, Irish W, Zervos E, Tuttle-Newhall J, Parikh A . Thirty-Day Morbidity after Simultaneous Resection of Colorectal Cancer and Colorectal Liver Metastasis: American College of Surgeons NSQIP Analysis. J Am Coll Surg. 2020; 230(4):617-627.e9. DOI: 10.1016/j.jamcollsurg.2019.12.018. View

3.
Fong Y, Fortner J, Sun R, Brennan M, Blumgart L . Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999; 230(3):309-18; discussion 318-21. PMC: 1420876. DOI: 10.1097/00000658-199909000-00004. View

4.
Mentha G, Majno P, Andres A, Rubbia-Brandt L, Morel P, Roth A . Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg. 2006; 93(7):872-8. DOI: 10.1002/bjs.5346. View

5.
Nishioka Y, Paez-Arango N, Boettcher F, Kawaguchi Y, Newhook T, Chun Y . Neither Surgical Margin Status nor Somatic Mutation Predicts Local Recurrence After R0-intent Resection for Colorectal Liver Metastases. J Gastrointest Surg. 2021; 26(4):791-801. PMC: 11875739. DOI: 10.1007/s11605-021-05173-0. View